Basilea Pharmaceutica AG (BPMUF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Basilea Pharmaceutica AG (BPMUF) trades at $60.27 with AI Score 58/100 (Grade B). Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company focused on developing products in oncology and anti-infectives. Market cap: $746M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BPMUF: BPMUF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BPMUF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BPMUF: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Basilea Pharmaceutica AG (BPMUF) Healthcare & Pipeline Overview
Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in oncology and anti-infectives, offering treatments like Cresemba and Zevtera. With a 17.9% profit margin and a beta of 0.46, the company focuses on addressing unmet medical needs through ongoing clinical trials and strategic product development within the biotechnology sector.
What Is the Investment Thesis for BPMUF?
Basilea Pharmaceutica AG presents a compelling investment case due to its established products and promising pipeline. With a market capitalization of $746M and a P/E ratio of 19.42, the company demonstrates financial stability and growth potential. Key value drivers include the continued commercial success of Cresemba and Zevtera, as well as the advancement of Derazantinib and Lisavanbulin through clinical trials. The company's 74.3% gross margin indicates strong pricing power and efficient operations. Upcoming clinical trial results and potential regulatory approvals for its pipeline candidates serve as significant growth catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
BPMUF Key Highlights
- Market Cap of $746M reflects investor confidence in Basilea's pipeline and commercial products.
- P/E ratio of 19.42 indicates a reasonable valuation compared to its earnings.
- Profit Margin of 17.9% demonstrates efficient operations and profitability.
- Gross Margin of 74.3% showcases strong pricing power and cost management.
- Beta of 0.46 suggests lower volatility compared to the overall market, making it a potentially stable investment.
Who Are BPMUF's Competitors?
BPMUF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
| GSGTF GenSight Biologics S.A. | $0.09 | +0.00% | $14.7M | 51 |
| INRLF Valneva SE | $2.77 | +5.73% | $525M | 57 |
| MDCLF MedinCell S.A. | $34.39 | +0.00% | $1.23B | 51 |
| RIGL Rigel Pharmaceuticals, Inc. | $39.67 | -2.15% | $734M | 94 |
| ZVRA Zevra Therapeutics, Inc. | $12.03 | -5.79% | $711M | 74 |
| MNPR Monopar Therapeutics Inc. | $105.90 | -4.70% | $709M | 70 |
| CLYM Climb Bio, Inc. | $12.22 | -3.78% | $833M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BPMUF's Key Strengths?
- Specialized expertise in oncology and anti-infectives.
- Commercialized products with established revenue streams.
- Promising pipeline of drug candidates in clinical trials.
- Strong gross margin.
What Are BPMUF's Weaknesses?
- Reliance on a limited number of products.
- High R&D expenses.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
What Could Drive BPMUF Stock Higher?
- Phase III clinical trial results for Cresemba in Japan for invasive fungal infections.
- Phase III clinical trial results for Zevtera in acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia.
- Phase 2 clinical trial progress for Derazantinib in bile duct cancer.
- Phase ½ clinical trial progress for Derazantinib in bladder and stomach cancer.
- Development progress of Lisavanbulin as a tumor checkpoint controller drug.
What Are the Key Risks for BPMUF?
- Financial-distress signal — its Altman Z-Score of 1.75 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for drug candidates.
- Regulatory delays or rejections.
- Competition from established pharmaceutical companies.
- Patent expirations and generic drug entry.
- Product liability claims.
What Are the Growth Opportunities for BPMUF?
- Expansion of Cresemba's Market Reach: Cresemba, Basilea's antifungal drug, has the potential for significant growth through geographic expansion and label extensions. The global market for antifungal drugs is projected to reach $17.5 billion by 2028. Securing regulatory approvals in additional markets, such as Japan, and expanding its use to treat other fungal infections could drive substantial revenue growth for Basilea.
- Advancement of Derazantinib in Oncology: Derazantinib, a small molecule inhibitor, is currently in Phase 2 clinical trials for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. The oncology market is one of the largest and fastest-growing segments in the pharmaceutical industry. Positive clinical trial results and subsequent regulatory approval could position Derazantinib as a valuable asset in Basilea's oncology portfolio, addressing a significant unmet medical need.
- Development of Lisavanbulin as a Tumor Checkpoint Controller: Lisavanbulin, a tumor checkpoint controller drug, represents a novel approach to cancer treatment. The market for immunotherapies and checkpoint inhibitors is experiencing rapid growth. Successful development and commercialization of Lisavanbulin could provide Basilea with a competitive advantage in the oncology space, capturing a significant share of the immunotherapy market.
- Lifecycle Management of Zevtera: Zevtera, Basilea's antibiotic, is currently in Phase III clinical trials for acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. Expanding the indications for Zevtera through successful clinical trials and regulatory approvals can extend its market exclusivity and drive revenue growth. The increasing prevalence of antibiotic-resistant bacteria underscores the need for new and effective antibiotics, creating a favorable market environment for Zevtera.
- Strategic Partnerships and Acquisitions: Basilea can pursue strategic partnerships and acquisitions to expand its pipeline and market reach. Collaborating with other biotechnology and pharmaceutical companies can provide access to new technologies, drug candidates, and markets. Acquiring complementary assets can strengthen Basilea's competitive position and accelerate its growth trajectory. These strategic initiatives can enhance Basilea's long-term value and create synergies across its operations.
What Opportunities Does BPMUF Have?
- Expansion into new geographic markets.
- Development of new drug candidates.
- Strategic partnerships and acquisitions.
- Lifecycle management of existing products.
What Threats Does BPMUF Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from generic drugs.
- Patent expirations.
What Are BPMUF's Competitive Advantages?
- Patented pharmaceutical products.
- Specialized expertise in oncology and anti-infectives.
- Established distribution network.
- Strong brand reputation.
What Does BPMUF Do?
Founded in 2000 and headquartered in Basel, Switzerland, Basilea Pharmaceutica AG is a biopharmaceutical company dedicated to developing and commercializing innovative products that address critical medical needs in oncology and anti-infectives. The company's portfolio includes Cresemba, an intravenous and oral azole antifungal drug used to treat invasive aspergillosis and mucormycosis. Cresemba is available in the United States and the European Union, and is currently in Phase III clinical trials in Japan for invasive fungal infections. Another key product is Zevtera, an antibiotic used for treating community and hospital-acquired pneumonia. Zevtera is also undergoing Phase III clinical trials for acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia. Basilea is also developing Derazantinib, a small molecule inhibitor in Phase 2 clinical trial for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. Additionally, they are developing Lisavanbulin, a tumor checkpoint controller drug. Basilea's strategic focus on these therapeutic areas positions it to capitalize on the growing demand for novel treatments in oncology and infectious diseases.
What Products and Services Does BPMUF Offer?
- Develop and commercialize pharmaceutical products.
- Focus on oncology and anti-infectives therapeutic areas.
- Offer Cresemba for the treatment of invasive aspergillosis and mucormycosis.
- Provide Zevtera for the treatment of community and hospital-acquired pneumonia.
- Engage in clinical trials for new drug candidates.
- Develop Derazantinib for bile duct, bladder, and stomach cancer.
- Develop Lisavanbulin as a tumor checkpoint controller drug.
How Does BPMUF Make Money?
- Develop and license pharmaceutical products.
- Generate revenue through product sales.
- Invest in research and development to expand product pipeline.
- Partner with other companies for commercialization and distribution.
What Industry Does BPMUF Operate In?
Basilea Pharmaceutica AG operates within the biotechnology industry, which is characterized by rapid innovation and high regulatory scrutiny. The market for anti-infectives and oncology drugs is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Basilea differentiates itself through its focus on specific therapeutic areas and its pipeline of novel drug candidates. The biotechnology industry is expected to continue its growth trajectory, fueled by advancements in genomics, personalized medicine, and drug delivery technologies.
Who Are BPMUF's Key Customers?
- Hospitals and healthcare providers.
- Patients with fungal infections and pneumonia.
- Oncology patients.
- Pharmaceutical distributors.
Company Profile
Basilea Pharmaceutica AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Allschwil, CH. The company is led by CEO David Veitch. BPMUF has traded publicly since 2015.
How Basilea Pharmaceutica AG Is Valued
Basilea Pharmaceutica AG carries a market capitalization of $746M, placing it in the small-cap category. Relative to its peer group, BPMUF's quantitative score of 58/100 is roughly in line with the peer average of 62/100.
ROE 28%Key Financial Metrics
Return on equity for Basilea Pharmaceutica AG stands at 28.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.5%, showing how much profit it generates from its asset base. BPMUF trades at a trailing price-to-earnings ratio of 19.61, below the Healthcare sector average of ~23x. Its free cash flow yield is 7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 8/9Financial Health
Basilea Pharmaceutica AG's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.75 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Basilea Pharmaceutica AG revenue of about $252.4M for fiscal 2026, with EPS near $4.27.
BPMUF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized expertise in oncology and anti-infectives.
- Commercialized products with established revenue streams.
- Promising pipeline of drug candidates in clinical trials.
- Strong gross margin.
Bear Case
- Reliance on a limited number of products.
- High R&D expenses.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BPMUF Latest News
No recent news available for BPMUF.
BPMUF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BPMUF.
Price Targets
Wall Street price target analysis for BPMUF.
BPMUF MoonshotScore
What does this score mean?
The MoonshotScore rates BPMUF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Veitch
CEO
David Veitch serves as the CEO of Basilea Pharmaceutica AG, bringing extensive experience in the pharmaceutical industry. His career spans various leadership roles in commercial operations, strategic planning, and business development. He has a proven track record of driving growth and innovation in the healthcare sector. His expertise lies in leading global teams and successfully launching pharmaceutical products in competitive markets. Veitch's background includes significant contributions to the development and commercialization of novel therapies.
Track Record: Under David Veitch's leadership, Basilea Pharmaceutica AG has focused on expanding its pipeline and strengthening its commercial presence. Key milestones include advancing clinical trials for Derazantinib and Lisavanbulin, as well as optimizing the market performance of Cresemba and Zevtera. He has also emphasized strategic partnerships to enhance the company's growth prospects and market reach.
BPMUF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Basilea Pharmaceutica AG (BPMUF) may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no reporting requirements, which increases investment risk. Trading on the OTC Other market differs significantly from exchanges like NYSE or NASDAQ, which have stringent listing standards and reporting obligations. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited Disclosure: Lack of comprehensive financial reporting increases information asymmetry.
- Low Liquidity: Difficulty in buying or selling shares without affecting the price.
- Price Volatility: Higher price fluctuations due to lower trading volumes.
- Regulatory Scrutiny: Potential for regulatory actions due to non-compliance.
- Going Concern Risk: Increased risk of financial distress or bankruptcy.
- Verify the company's financial statements and audit reports.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Established Products: Commercialized products like Cresemba and Zevtera indicate a viable business.
- Clinical Trials: Ongoing clinical trials suggest continued investment in research and development.
- Experienced Management: Presence of an experienced CEO like David Veitch.
- Partnerships: Strategic alliances with other companies can validate the business model.
- Scientific Publications: Peer-reviewed publications supporting their research.
BPMUF Healthcare Stock FAQ
What does the AI Score mean for BPMUF?
BPMUF holds an AI Score of 58/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company focused on developing products in oncology and anti-infectives. Its key products include Cresemba, an antifungal, …
What does Basilea Pharmaceutica AG do?
Basilea Pharmaceutica AG is a biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products in the therapeutic areas of oncology and anti-infectives. The company's portfolio includes commercialized products such as Cresemba, an antifungal, and Zevtera, an antibiotic, which are marketed to hospitals and healthcare providers.
What are the main risks for BPMUF?
The main risks for Basilea Pharmaceutica AG include the potential for clinical trial failures, which could significantly impact the company's pipeline and future revenue prospects. Regulatory hurdles and delays in obtaining approvals for new drugs also pose a risk. Competition from larger pharmaceutical companies with greater resources and established market presence is another factor.
What are the key factors to evaluate for BPMUF?
Basilea Pharmaceutica AG (BPMUF) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does BPMUF data refresh on this page?
BPMUF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BPMUF's recent stock price performance?
Basilea Pharmaceutica AG (BPMUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in oncology and anti-infectives. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BPMUF overvalued or undervalued right now?
Basilea Pharmaceutica AG (BPMUF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BPMUF before investing?
Before investing in Basilea Pharmaceutica AG (BPMUF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BPMUF to a portfolio?
Key strength of Basilea Pharmaceutica AG (BPMUF): Specialized expertise in oncology and anti-infectives. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.